Baer H U, Friess H, Abou-Shady M, Berberat P, Zimmermann A, Gold L I, Korc M, Büchler M W
Department of Visceral and Transplantation Surgery, University of Bern, Switzerland.
Eur J Gastroenterol Hepatol. 1998 Dec;10(12):1031-9. doi: 10.1097/00042737-199812000-00009.
Transforming growth factor betas (TGF-betas) are a group of homologous polypeptides that exert pleiotropic effects on various cell types and stimulate the formation of extracellular matrix and fibrosis. To evaluate whether TGF-beta isoforms (TGF-beta1, TGF-beta2 and TGF-beta3) and their receptors (types I-III) are also of importance in the pathophysiology of liver cirrhosis, we analysed their concomitant expression and localization in human liver cirrhosis.
Cirrhotic liver tissue samples were obtained from 17 patients (four women, 13 men) with a median age of 41 years (range 22-67). Normal liver tissues from ten patients (seven women, three men) with a median age of 55 years (range 45-75) served as controls.
The tissues were fixed in Bouin's solution and paraffin-embedded for histological analysis. For RNA analysis, freshly obtained tissue samples were snap-frozen in liquid nitrogen and stored at -80 degrees C until analysed. Northern blot analysis was used to examine the expression of TGF-beta1, beta2 and beta3 and their receptors, type I (TbetaR-I), type II (TbetaR-II) and type III (TbetaR-III). Immunohistochemistry was performed to determine the localization of the corresponding proteins in the normal and the cirrhotic liver.
Northern blot analysis revealed enhanced expression (P < 0.05) of TGF-beta1 (twofold increase), TGF-beta2 (threefold increase) and TGF-beta3 (8.5-fold increase) and of TbetaR-II (threefold increase) mRNA in liver cirrhosis in comparison with normal controls. In contrast, TbetaR-I (ALK-5) and TbetaR-III mRNA expression showed no significant changes. No TGF-beta isoform immunoreactivity was present in hepatocytes in either normal livers or in liver cirrhosis. However, in liver cirrhosis, intense TGF-beta1 immunoreactivity was present in bile duct and ductular epithelial cells (including ductular proliferations) and in inflammatory cells. In a few sinusoidal lining cells, faint TGF-beta1 and moderate TGF-beta2 immunoreactivity was present. TGF-beta3 immunostaining was present in bile duct and ductular epithelial cells, in inflammatory cells and in fibroblast-like spindle cells in liver cirrhosis. For TbetaR-I and TbetaR-II, the immunoreactivity was localized in hepatocytes and biliary cells in normal and cirrhotic liver tissues, with higher intensity for TbetaR-II in the cirrhotic liver.
Enhanced expression of all three TGF-bea isoforms and of TbetaR-II in liver cirrhosis suggests their involvement in this fibrotic disorder. The higher immunoreactivity of the three TGF-beta isoforms in the bile duct epithelial cells in cirrhotic tissues suggests a possible role of these cells in the pathogenesis of liver cirrhosis.
转化生长因子β(TGF-β)是一组同源多肽,对多种细胞类型发挥多效性作用,并刺激细胞外基质的形成和纤维化。为了评估TGF-β亚型(TGF-β1、TGF-β2和TGF-β3)及其受体(I-III型)在肝硬化病理生理学中是否也具有重要意义,我们分析了它们在人类肝硬化中的伴随表达和定位。
从17例患者(4名女性,13名男性)获取肝硬化肝组织样本,中位年龄41岁(范围22-67岁)。来自10例患者(7名女性,3名男性)的正常肝组织作为对照,中位年龄55岁(范围45-75岁)。
组织用Bouin溶液固定并石蜡包埋用于组织学分析。对于RNA分析,新鲜获取的组织样本在液氮中速冻并储存在-80℃直至分析。采用Northern印迹分析检测TGF-β1、β2和β3及其受体I型(TβR-I)、II型(TβR-II)和III型(TβR-III)的表达。进行免疫组织化学以确定相应蛋白在正常和肝硬化肝脏中的定位。
Northern印迹分析显示,与正常对照相比,肝硬化中TGF-β1(增加两倍)、TGF-β2(增加三倍)、TGF-β3(增加8.5倍)以及TβR-II mRNA(增加三倍)表达增强(P<0.05)。相比之下,TβR-I(ALK-5)和TβR-III mRNA表达无显著变化。正常肝脏和肝硬化肝脏的肝细胞中均未检测到TGF-β亚型免疫反应性。然而,在肝硬化中,胆管和小胆管上皮细胞(包括小胆管增生)以及炎症细胞中存在强烈的TGF-β1免疫反应性。在少数窦状隙衬里细胞中,存在微弱的TGF-β1和中等强度的TGF-β2免疫反应性。肝硬化中,TGF-β3免疫染色存在于胆管和小胆管上皮细胞、炎症细胞和成纤维样梭形细胞中。对于TβR-I和TβR-II,免疫反应性定位于正常和肝硬化肝组织中的肝细胞和胆管细胞,在肝硬化肝脏中TβR-II强度更高。
肝硬化中所有三种TGF-β亚型和TβR-II的表达增强表明它们参与了这种纤维化疾病。肝硬化组织中胆管上皮细胞中三种TGF-β亚型较高的免疫反应性表明这些细胞在肝硬化发病机制中可能起作用。